GlassScriptPhysician profile
Marla H Daves
NPI 1437392974
$1,202.21
in general payments reported to CMS, 2019-2025
11 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2024: $547 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $795.77 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $349.15 | 2019-2025 | |
| Chiesi USA, INC. | $300.00 | 2025 | Ferriprox |
| Pharming Healthcare, INC. | $172.60 | 2024 | Joenja, Ruconest |
| Amgen INC. | $118.37 | 2024 | Blincyto |
| Uswm, LLC | $59.30 | 2024-2025 | Iwilfin |
| Bayer Healthcare Pharmaceuticals INC. | $57.80 | 2024-2025 | |
| Pfizer INC. | $44.63 | 2024 | |
| Rare Disease Therapeutics, INC. | $36.38 | 2024-2025 | Purixan, Xromi |
| Servier Pharmaceuticals LLC | $24.14 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.55 | 2025 | Ultomiris |
| Adaptive Biotechnologies Corporation | $19.29 | 2025 | Clonoseq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Daves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.